REVB Latest Press Releases

-- August 19, 2026 --

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study Business Wire 9:00 AM

-- August 6, 2026 --

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 ACCESS Newswire 4:15 PM

-- August 3, 2026 --

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury ACCESS Newswire 9:00 AM

-- July 21, 2026 --

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESS Newswire 4:05 PM

-- July 10, 2026 --

Revelation Biosciences Announces Adoption of Stockholder Rights Plan ACCESS Newswire 4:05 PM

-- June 1, 2026 --

Revelation Biosciences Expands Acute Kidney Injury Advisory Board ACCESS Newswire 9:00 AM

-- May 11, 2026 --

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders ACCESS Newswire 9:00 AM

-- May 7, 2026 --

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 ACCESS Newswire 4:16 PM

-- April 6, 2026 --

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board ACCESS Newswire 9:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software